# The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes

> **NCT07373236** · NA · COMPLETED · sponsor: **Asger Lund, MD** · enrollment: 12 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** exendin(9-39)amide
- **DRUG:** Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT07373236
- **Lead sponsor:** Asger Lund, MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-01-23
- **Primary completion:** 2026-04-09
- **Final completion:** 2026-04-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07373236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07373236, "The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07373236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*